Podcasts about aace

Join AACE Past President and endocrinologist Dr. Susan Samson as she leads a compelling roundtable discussion highlighting the importance of the endocrine care team model. She is joined by nurse practitioner Dominique Uva, physician associate Sonia Bahroo, nurse scientist and diabetes educator Dr. Julia Blanchette, endocrine pharmacist Dr. Diana Isaacs, and nurse practitioner and clinical professor Dr. Chris Yedinak. Together, they explore how multidisciplinary care teams are essential to addressing the growing burden of endocrine diseases such as diabetes and thyroid disorders. Each expert shares how they collaborate across disciplines to improve access, provide patient support, and extend specialist care, especially in underserved communities. Tune in for practical insights, collaborative strategies, and a deeper look into how team-based care can elevate endocrine health outcomes.

Video Version Only on HCPLive! In this episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, co-hosts Diana Isaacs, PharmD, BCPS, BC-ADM, CDCES, FADCES, and Natalie Bellini, DNP, FNP-BC, provide a comprehensive review of the 2025 American Association of Clinical Endocrinology (AACE) Annual Meeting held in Orlando, Florida. The episode captures notable sessions, emerging clinical insights, and advances in diabetes care and endocrinology presented during the conference. The discussion opens with reflections on keynote lectures, including a plenary led by Daniel Drucker, MD, on incretin physiology and the clinical evolution of GLP-1 receptor agonists. Isaacs highlights the importance of his translational research and addresses the implications of safety concerns such as pancreatitis and thyroid cancer. Both hosts express admiration for Drucker's role in shaping the field of incretin-based therapies. Another highlight includes the plenary delivered by Anne L. Peters, MD, which emphasized health equity and expanding access to diabetes technology in underserved populations. Isaacs discusses Peters' innovative use of pharmacists in insulin pump clinics and her longstanding contributions to ADA standards of care. Bellini commends Peters' dual impact in both affluent and marginalized communities. The hosts also describe their participation in a hands-on diabetes technology workshop, where attendees rotated through device-specific stations including insulin pumps, CGMs, inhaled insulin, and smart pens. This workshop was part of a broader effort to launch a diabetes technology certification program, with both in-person and online components scheduled for release in summer 2025. Clinical trial updates included coverage of the CONTROL-IQ Plus RCT in type 2 diabetes, studies on weekly insulin formulations, CGM use in inpatient settings, and the Inhale-3 trial on inhaled insulin efficacy. Discussions also touched on advancements in over-the-counter CGMs, data interpretation challenges in individuals without diabetes, and the proposed shift toward using time-in-normal glucose range (TING) metrics to assess glycemic control. The episode concludes with enthusiasm for the future of patient-centered technology and anticipation for the AACE 2026 meeting in Las Vegas. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others.

In this episode, Dr. Jaime Almandoz, Associate Professor of Medicine at UT Southwestern, is joined by Dr. Robert F. Kushner, Professor of Medicine at Northwestern University and a leading authority in obesity medicine, to discuss the recent Lancet Diabetes & Endocrinology Commission report, “Definition and Diagnostic Criteria of Clinical Obesity.” The report introduces a new framework for defining clinical and preclinical obesity, aiming to move beyond the limitations of BMI. Dr. Kushner shares insights into the Commission's global consensus process and how the updated definitions can transform care, reduce weight stigma, and support more targeted treatment. Don't miss this timely conversation on the evolving future of obesity diagnosis and management.

Join 2025 Annual Meeting Chair, Cecilia Low Wang, MD, FACP, FACE, as she interviews Rachna Relwani, MD, Chair of the Environmental Endocrinology Topic Interest Group (TIG), and David C. Lieb, MD, FACP, FACE, Chair of the Artificial Intelligence and Clinical Endocrinology TIG. In this episode, you'll gain insight into how these TIGs are advancing critical conversations, fostering collaboration through AACE's new Facebook Groups, and preparing for engaging meetups at the AACE Annual Meeting in Orlando, May 15–17. Whether you're passionate about environmental health or curious about the role of AI in clinical practice, this episode offers a dynamic preview of what's ahead.

Join Dr. David Lieb as he moderates a discussion with Dr. Jaydira Del Rivero, Chair of the MEN1 Consensus Statement Task Force, and Dr. Michelle Lundholm, Methodology Fellow, about the recently released 2025 AACE Consensus Statement on the Management of Multiple Endocrine Neoplasia, Type 1 (MEN1).This episode covers:AACE's updated consensus statement methodology, including the new methodology fellow and patient representative rolesThe role of surgical and non-surgical management strategies for patients with different types of MEN1-related tumorsThe importance of patient values and preferences and risks/benefits of different screening modalities when determining appropriate screening frequencies for patientsCurrent gaps in the literature and future considerations for MEN1 research

Guideline AACE 2025: quais as recomendações sobre o ácido bempedoico?

Guideline AACE 2025: há recomendação para uso do Inclisiram?

Guideline AACE 2025: quais as recomendações sobre os inibidores da PCSK-9?

Guideline AACE 2025: avaliação de risco cardiovascular na prevência primária

Novo Guideline de Dislipidemia do AACE

Early detection and monitoring of Type 1 Diabetes (T1D) are crucial for improving patient outcomes and quality of life. Join clinical experts Lubaina S. Presswala, DO, FACOI, FACE; Jeff Unger, MD, FAAFP, FACE, DACD; and Javier Morales, MD, FACP, FACE, as they discuss the growing prevalence of T1D, the importance of autoantibody screening, the different stages of T1D, screening guidelines, patient counseling, and how early intervention can help delay progression and reduce complications. Support for this podcast is provided by Sanofi.

Join Dr. David Lieb as he moderates an engaging discussion with Dr. Shailendra Patel, Chair of the Dyslipidemia Guideline Task Force, and Dr. Kathleen Wyne, Vice Chair, about the recently released 2025 AACE Clinical Practice Guideline on Pharmacologic Management of Adults with Dyslipidemia.This episode covers:What's new or different in this update compared to the 2017 guideline.Surprising insights revealed during the evidence assessments and how they shaped the recommendations.Key considerations for clinicians as they integrate these updated recommendations into practice.Gaps in the literature and opportunities for future research.Whether you're familiar with the previous guideline or new to this topic, this conversation provides a comprehensive overview of the latest advancements in dyslipidemia management.

In this episode, join moderator Dr. David Lieb alongside esteemed panelists Dr. Shahnaz Sultan, Dr. Carol Peng, and Dr. Melanie Bird as they delve into the methodology behind the 2025 AACE Clinical Practice Guideline on Pharmacologic Management of Adults with Dyslipidemia.Discover insights into:Why AACE adopted the GRADE framework and its implications for guideline development.The critical role of systematic reviews in creating evidence-based recommendations.How evidence is assessed using the GRADE approach.Practical takeaways for clinicians when implementing GRADE-informed guidelines in patient care.Whether you're a seasoned practitioner or new to the field, this discussion offers valuable perspectives on the evolution of evidence-based guideline development and its impact on clinical practice.

Join endocrine expert Cheryl Rosenfeld, DO, FACE, FACP, FSVM, ECNU, for a special AACE Podcast featuring her patient, Andree. Together, they explore Andree's personal journey with thyroid disease and how the AACE Journey for Patients With Thyroid Disease website has been an invaluable resource, offering clear and accessible tools to navigate her thyroid condition with confidence. Don't miss this inspiring discussion, brought to you with the support of AbbVie and Amgen Rare Disease.

Join endocrine experts Vin Tangpricha, MD, PhD, FACE, Editor-in-Chief of Endocrine Practice (EP) and Professor of Medicine at Emory University School of Medicine, and Rifka C. Schulman-Rosenbaum, MD, FACE, FACP, Director of Inpatient Diabetes at Long Island Jewish Medical Center, Professor of Medicine at the Donald and Barbara Zucker School of Medicine at Northwell Health, and Chair Elect for the AACE 2025 Annual Meeting, as they discuss Dr. Schulman-Rosenbaum's EP article, “Sodium-Glucose Cotransporter 2 Inhibitors Should Be Avoided for the Inpatient Management of Hyperglycemia.” Tune in as they explore the complexities of managing inpatient hyperglycemia, the risks of SGLT-2 inhibitors in hospitalized patients, and who might be good candidates for safer alternatives like DPP-4 inhibitors and insulin. Packed with valuable insights and practical strategies, this discussion is essential for optimizing hospital-based diabetes care. Read the full article in the April 2024 issue of EP here.

Join endocrine experts Vin Tangpricha, MD, PhD, FACE, Editor-in-Chief of Endocrine Practice (EP) and Professor of Medicine at Emory University School of Medicine, and Cecilia C. Low Wang, MD, FACE, FACP, Professor of Medicine and Medical Director for the Glucose Management Team at the University of Colorado, as they discuss Dr. Low Wang's impactful EP article titled "Safety and Efficacy of Insulins in Critically Ill Patients Receiving Continuous Enteral Nutrition." Tune in as they explore strategies for managing hyperglycemia and hypoglycemia in hospitalized patients on continuous tube feeds, evaluate insulin regimens such as 70/30 Q-8 hours and basal-bolus, examine differences in glycemia management for patients with and without diabetes, and discuss ways to optimize glycemic control. View the full article in the April 2024 issue of EP here.

Direto do Congresso Internacional do IBDiC, o Instituto Brasileiro de Direito da Construção, o Capital Projects Podcast traz mais uma série especial! Onde a Engenharia e o Direito se encontram, vocês terão aqui muitas discussões sobre temas ligados à gestão contratual e resolução de disputas! Nesse oitavo e penúltimo episódio da série, eu converso sobre arranjos colaborativos em Contratos de Construção com Rafael Monteiro. Rafael é sócio da prática de Infraestrutura & Projetos de Capital da Deloitte e Mestre em engenharia com foco em contratos internacionais de construção pela Universidade de Stuttgart. Liderou projetos no Brasil, Peru, México e Moçambique e dedica-se ao desenvolvimento de relações colaborativas entre investidores e construtores. É também membro da DRBF, AACE e SCL, e ganhador do Prêmio IBDiC 2023. Vamos falar sobre como podemos ter abordagens mais colaborativas entre Contratantes e Contratadas? Dê um play e vamos juntos! Para saber mais sobre os próximos eventos apoiados pelo Capital Projects Podcast, acesse: - 16° Congresso de Gestão, Projetos e Liderança do PMI MG, que vai acontecer em Belo Horizonte nos dias 22 e 23 de novembro: www.pmimg.org.br - 22° Seminário Internacional de Gerenciamento de Projetos do PMI SP, que vai acontecer nos dias 26 e 27 de novembro em São Paulo: www.pmisp.org.br (eu estarei lá!) - 23° Encontro de Gerenciamento de Projetos do PMI DF, que vai acontecer em Brasília de 26 a 28 de novembro: https://pmidf.org/egp/ Essa série só foi possível graças ao apoio especial da Deloitte (https://www.deloitte.com/br/pt.html) e do IBDiC (https://ibdic.org.br/)! Quer entrar no para saber em primeira mão sobre as lives e a nova turma do Curso GPI/FEL? Acesse: https://chat.whatsapp.com/KZNt0vR1zLfBt4ZeqflVGN #CapitalProjectsPodcast #GestãodeProjetos #CapitalProjects #AndreChoma #Construção #Engenharia #ProjectManagement #PMI #ProjectManagementInstitute #FEL #Frontendloading #MetodologiaFEL #Deloitte #IBDiC #GestãodeContratos #ContratosColaborativos #IPD #IntegratedProjectDelivery #RafaelMonteiro

Discover insights into the challenging landscape of Cushing syndrome, where adrenal variations require careful diagnostic and therapeutic strategies. In this podcast, Sina Jasim, MD, MPH, Editor-in-Chief of the AACE Clinical Reports (ACCR) and Associate Professor of Medicine at Washington University School of Medicine, leads a compelling discussion on two unique cases featured in the ACCR article, Histopathologic Differences Between Adrenocorticotropic Hormone–Dependent and Adrenocorticotropic Hormone–Independent Adrenal Hyperplasia Causing Cushing Syndrome. Authors, Amir H Hamrahian, MD, Endocrinologist, Associate Professor, and Medical Director of the Comprehensive Adrenal Center at Johns Hopkins University School of Medicine, and Ezra Baraban, MD, Assistant Professor of Pathology at Johns Hopkins University School of Medicine, explain the diagnostic challenges for each case, the decision-making process between medical and surgical approaches, and the critical role of pathology in guiding clinical care. Read the full case report in ACCR at https://www.aaceclinicalcasereports.com/article/S2376-0605(22)00066-9/fulltext.

Obesity is a complex, chronic disease of excessive or abnormally accumulated body fat that significantly increasing the risk of various medical conditions. As the most prevalent chronic disease in the United States—affecting 40% of the population—and impacting 1 in 8 people globally, finding reliable, clinically accurate, and patient-friendly information online can be challenging. To address this gap, AACE developed the “AACE Journey for Patients With Obesity,” a comprehensive resource designed to empower people with obesity to navigate their condition, treatment options, and wellness goals. In this episode, leading endocrinologists Elizabeth Bauer, MD, FACP; Cheryl Rosenfeld, DO, FACE, FACP, FSVM, ECNU; and Kenneth Izuora, MD, MBA, FACE, discuss the journey's development using the latest guidelines, including the integration of adiposity-based chronic disease (ABCD) terminology, which addresses the stigma associated with obesity. They also highlight the collaboration with the Obesity Action Coalition to ensure the resource is patient-centered and explain how both patients and health care professionals can utilize it to enhance care and improve outcomes. Support for this podcast was provided in part by Lilly and Boehringer Ingelheim.

Join Maria A. Mogollon, MSN, APRN, FNP-BC, a Diabetes and Obesity Nurse Practitioner and former Internal Medicine physician in Venezuela, and Jeff Unger, MD, FAAFP, FACE, DACD, Director, Unger Primary Care Concierge Medical Group, renowned Board-Certified Family Physician, Diabetologist, and co-author of the AACE 2021 Clinical Practice Guideline for the Use of Advanced Technology in the Management of Persons with Diabetes Mellitus, as they delve into crucial topics in diabetes technology. Key topics discussed include the benefits and cost-effectiveness of continuous glucose monitors (CGM) compared to traditional finger-stick methods, practical implementation into practice workflows, interpreting CGM data, and identifying ideal candidates for CGM use. Through case studies and practical examples, they address common concerns and barriers to CGM adoption, providing valuable insights for healthcare professionals on how to have effective conversations with patients and integrate CGM technology into patient care.

Join endocrine experts Ty Carroll, MD, Associate Professor of Medicine at the Medical College of Wisconsin, and Vin Tangpricha, MD, PhD, FACE, Editor-in-Chief of Endocrine Practice (EP) and Professor of Medicine at Emory University School of Medicine, as they delve into Dr. Carroll's groundbreaking EP article titled "Hormonal Contraceptive Use Is Associated With a Decreased Incidence of Hypothyroidism." Tune in as they discuss the study findings on the association between hormonal contraceptive use and reduced hypothyroidism risk, along with its limitations and implications for future research. View the full article in the Jan. 2024 issue of EP at https://www.endocrinepractice.org/article/S1530-891X(23)00715-2/abstract.

The frequency of hematospermia in transgender women is unknown, indicating a gap in current medical understanding. Join medical experts Tamar Reisman, MD, Clinical Endocrinologist at New York Presbyterian Weill Cornell Medical Center, and Sina Jasim, MD, MPH, ACCR Editor-in-Chief and Associate Professor of Medicine at Washington University School of Medicine, as they delve into a groundbreaking clinical case report titled "Hematospermia in a Transgender Woman with Evidence for Endometrial Tissue in the Prostate." Tune in as they discuss the highlights of the case, when to screen for endometriosis or ectopic Müllerian epithelial tissue growth in transgender women undergoing feminizing gender-affirming hormone therapy, and how to address challenges and barriers to patient care. View the full report in the Jan. 2024 issue of ACCR at https://doi.org/10.1016/j.aace.2024.01.006.

Thyroid disease affects approximately 20 million Americans, leading many patients to turn to the internet for answers. However, amidst the vast array of information available online, distinguishing accurate information can be challenging. Recognizing this necessity, the endocrine experts at AACE have developed "The Journey For Patients With Thyroid Disease," an innovative resource devoted to educating and empowering individuals with thyroid disease to navigate their condition, treatment plan, and wellness goals. In this podcast, endocrine experts Alex Tessnow, MD, ECNU, FACE, Cheryl Rosenfeld, DO, FACE, FACP, FSVM, ECNU, and Kenneth Izuora, MD, MBA, FACE, delve into the development, significance, and accessibility of this patient resource. Key topics discussed include the meticulous crafting of the journey into a meta-map using the latest AACE guidelines, the importance of providing patients with resources beyond the clinical setting, and how this resource serves as an invaluable tool for both patients and clinicians, providing timely updates on the latest clinical advancements for thyroid care. Support for this podcast was provided in part by AbbVie.

Join endocrine expert Janet B. McGill, MD, MA, FACE, FACP, Professor of Medicine in the Division of Endocrinology, Metabolism and Lipid Research at Washington University School of Medicine, and moderator Sina Jasim, MD, MPH, ACCR Editor-in-Chief, Associate Professor of Medicine, and Endocrine Neoplasia Specialist at Washington University School of Medicine, as they discuss diabetes clinical case reports from the July/August 2023 issue of ACCR. Dr. McGill presents two key cases, MODY5 and Serous Ovarian Carcinoma in 17q12 Recurrent Deletion Syndrome, — a case of a young woman whose monogenic diabetes was diagnosed after a pathogenic ~1.8 Mb loss of 17q12 was found on the chromosomal microarray of her serous ovarian carcinoma and identifying a disease association not previously reported. The second case was on the maturity-onset of diabetes of the young (MODY), ABCC8-Related Monogenic Diabetes Presenting Like Type 1 Diabetes in an Adolescent, — a case of type 1 diabetes diagnoses during adolescence, and how the patient was treated with intensive insulin therapy for 17 years before genetic testing showed a pathogenic mutation of the ABCC8 gene. Access the key teaching points and view the full cases of MODY5 and Serous Ovarian Carcinoma in 17q12 Recurrent Deletion Syndrome at: https://www.aaceclinicalcasereports.com/article/S2376-0605(23)00093-7/fulltext and ABCC8-Related Monogenic Diabetes Presenting Like Type 1 Diabetes in an Adolescent at: https://www.aaceclinicalcasereports.com/article/S2376-0605(23)00086-X/fulltext

Parathyroid cysts (PC) are a rare cause of neck masses, with an ectopic intrathyroidal location being even more rare. Join endocrine experts Victor J. Bernet, MD, FACE, FACP, Director, Endocrinology, Diabetes and Metabolism Fellowship Program at the Mayo Clinic in Florida, and Sina Jasim,  MD, MPH, ACCR Editor-In-Chief, Associate Professor of Medicine, and Endocrine Neoplasia Specialist at Washington University School of Medicine, as they discuss the clinical case report, A Middle-aged Woman With Recurrent Intrathyroidal Parathyroid Cyst Treated With Ethanol Sclerotherapy, which presents a case of a recurrent intrathyroidal cyst successfully treated with ethanol sclerotherapy. Key topics discussed include the sclerosis efficacy in orthotopically positioned PCs, how ethanol sclerotherapy is an effective treatment option for recurrent intrathyroidal PCs, and important teaching points of this case. Visit https://www.aaceclinicalcasereports.com/article/S2376-0605(23)00131-1/fulltext to read the full AACE Clinical Case Report.

Surfing the MASH Tsunami continues its 2023 wrap-up conversations with Global Liver Institute Founder and CEO Donna Cryer, along with co-hosts Louise Campbell and Roger Green. The conversation focuses on Donna's personal health challenges in late 2023, what her absence revealed about the strength and depth of the GLI team, and what she foresees as major challenges for 2024. The conversation starts with Donna discussing a major medical event in her life during the last few months in 2024, one during which, in her words, "I almost died." She speaks briefly but clearly about the nature of the event itself, as well as how and why she is rebounding to full strength. Donna goes on to describe how well the GLI team performed in her absence and the various forms of feedback she received confirming this. In response to a question from Louise, she notes that building a strong team has always been her priority at GLI and cites several past examples where the team has led while she assumed other roles and challenges. From here, Donna notes a major change in 2023: the evolution from being a liver community to what she describes as "a community that cares about the liver," a multi-specialty, multi-stakeholder group focused on the wider implications of liver disease and patient and public health. As examples of this broader community, she cites the common guidelines from AACE and AASLD, conversations with payers and a willingness from other liver disease groups to share capabilities with the SLD community. She goes on to note that none of this change happens quickly, but that in the 10 years since GLI was formed, the scale of change has been consequential.The discussion turns toward the process of nomenclature change. Donna notes her concern throughout the process that some important implementation steps were not being considered on as timely or thorough a basis as she would have hoped. Specifically, she cites the issue of ICD codes and the need to involve primary care providers and organizations into the key processes. Louise Campbell agrees, noting the challenges around bringing wider use of VCTE into the UK system even after NICE has accepted the need to do so. Donna notes that this is the reason that GLI is calling its annual event Global Fatty Liver Day, not to be "recalcitrant, but because, as a global organization, we recognize" that not all parts of the world have adopted this nomenclature. She anticipates using what she calls "bridging documents" so that people using different nomenclatues can explain the same processes. From here, the conversation transitions to cover the growing momentum and energy in the patient and advocate communities, as evidenced by general energy and Roger's experience (along with Mike Betel) of getting pushed out of overflow rooms for patient sessions at AASLD (listen to E50.2 for more details). Finally, the conversation returns to the value of the MetALD classification, some issues around Donna's recent health scare, and a promising view of the future.

Surfing the MASH Tsunami continues its 2023 wrap-up conversations with hepatology researcher and key opinion leader Naim Alkhouri of the Arizona Liver Health Institute, along with co-hosts Louise Campbell and Roger Green. The conversation focuses on viewing the year's major events in drug development, non-invasive tests (NITs) and clinical care pathways.This conversation starts with Roger asking Naim his reaction to 2023. Naim starts by mentioning his disappointment that OCA did not get approved but shares his vision that the data presentation did not support approval and his hope and belief that resmetirom will fare better. From there, he shifts quickly to discuss being "a little bit disappointed" at the implementation of the AACE and AGA guidelines. In practical terms, he has not seen a single referral from primary care practices (PCP) for elevated FIB-4. He notes that this will require better education of PCPs, but also expresses concern that the guidelines might not be practical for them. In the effort "not to miss a single patient," he believes, authors have created a system with too many patients screened, found negative, and sent back to the PCP. Instead, he suggests, guidelines should have a more realistic goal (reducing unidentified patients from 95% to 80%) and rely on higher FIB-4 cutoffs until PCPs have integrated the concept of MASH screening into their practices. Wrapping up his view of 2023, he describes it as a "good year," although unfortunately one in which drug approval and increased pathway use did not occur.Roger suggests that the same phenomenon -- worrying more about making things perfect than making them implementable -- applied to the original rollout of the new nomenclature as well as pathways, and goes on to discuss what he sees as the behavioral psychology implications of the pathway guidelines. Naim responds with two suggestions: raise the minimum PIB-4 score at which patients are referred to 2.67 and, in the US, reflex to an ELF test before sending patients to specialists. Louise notes that ELF is not as readily available in the UK as Americans might assume. Roger adds that it might be of value to educate PCPs on the value of FIB-4 as predictive of MACE and other forms of mortality.Roger asks Naim to describe the "biggest wins" of 2023. Naim starts by citing specific advances in NITs, specifically mentioning NIS-2+ and MASEF (discussed in S4 E39). In terms of medications, he discussed the double- and triple-incretin agonists and their ability to support patients in defatting their livers and notes that, of course, resmetirom's positive Phase 3 results are the biggest story. His third item is the expansion of multi-specialty meetings that educate other specialties on SLD, why it matters, and what roles the other specialties can play in diagnosing and managing MASH patients. Roger's next question is about disappointments. Naim wishes FDA had moved further and faster in alternate drug approval pathways and metrics, but sees progress in terms of their openness to exploring NITs and, more exciting, their recently stated willingness to grant full approvals in cirrhosis based on histology. Roger asks how AI fits into the emerging picture. Naim states that AI analyses can teach a great deal about the disease, but is not practical for patient treatment. The last question: his most optimistic picture for 2024 starts with resmetirom approval, goes on to mention several exciting potential drug development results and then discusses creating MASL Centers of Excellence relying on robust NITs for diagnosis and management. 

Minimally invasive procedures are now more widely used for benign and some low-risk cancerous thyroid tumors. In certain cases of papillary thyroid microcarcinomas; and if those are positioned in a favorable location, Radiofrequency Ablation (RFA) offers a less invasive treatment option compared to traditional surgical approaches. Listen to Leonardo Guimarães Rangel, MD, Head and Neck Surgeon in Rio de Janeiro, Brazil, and international expert in minimally invasive procedures in thyroid tumors, present his Visual Vignette on Radiofrequency Ablation of Papillary Thyroid Microcarcinomas,  moderated by Sina Jasim, MD, MPH, Associate Professor of Medicine, and Endocrine Neoplasia Specialist at Washington University School of Medicine. Key topics include procedure safety, determining the right patient and nodule candidate, follow-up care, challenges, and future outcomes. Visit https://www.aaceclinicalcasereports.com/article/S2376-0605(22)00010-4/fulltext to view and read the full AACE Visual Vignette.

Join clinical experts David Lieb, MD, FACE, Jennifer N. Clements, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM, and Vin Tangpricha, MD, PhD, FACE, as they discuss the 2022 AACE diabetes guideline updates and address the issue, “How Should Hypoglycemia Be Managed?” Key topics include how to put the guideline into practice particularly in primary care settings, how to characterize which people with diabetes should be prescribed glucagon to manage low blood sugar levels, and how to incorporate ready-to-use glucagon into hypoglycemia treatment plans for people with diabetes. Support for this podcast is provided by Xeris Pharmaceuticals, Inc.

Join endocrine experts Ricardo Correa, MD, FACP, FACMQ, FAPCR, FACE; Rajesh Garg, MD, PhD; and Geetha Gopalakrishnan, MD, FACE, as they share valuable tips and success stories on how to talk to patients with diabetes about the importance of vaccinations in diabetes management. Key topics include strategies for addressing barriers in workflows, differences in cultural norms and vaccine hesitancy. AACE endocrine experts share available patient resources along with a wealth of information aimed at enhancing your interactions with patients. 

AACE has revised its policies and adopted a new methodology for guideline and consensus statement development to support the mission to elevate the practice of clinical endocrinology to improve patient care. Join endocrine experts Ricardo Correa, MD, FACP, FACMQ, FAPCR, FACE, Joanna Miragaya, MD, PhD, FACE, and Vin Tangpricha, MD, PhD, FACE, as they dive into the 2023 protocol updates. Key topics include updates to methodology, processes, and policies. Visit https://www.endocrinepractice.org/article/S1530-891X(23)00032-0/fulltext to view the protocol in the May 2023 issue of Endocrine Practice.

Wolfram syndrome (WS) is a rare genetic disorder in which patients develop early-onset diabetes mellitus (DM), optic nerve atrophy, and neurodegeneration, which has no specific treatment available. Listen to endocrine experts Fumihiko Urano, MD, PhD. Samuel E. Schechter Professor of Medicine at Washington University School of Medicine, and Sina Jasim, MD, MPH, Associate Professor of Medicine at Washington University School of Medicine, discuss a new clinical case report on two patients with Wolfram syndrome who were initially diagnosed with type 1 diabetes but were negative for islet autoantibodies. Key topics include the importance of distinguishing between Wolfram syndrome and type 1 diabetes, the significance of the homozygous vs. compound heterozygous pathogenic variants in WFS1 gene, how the management and treatment for Wolfram syndrome differs from that of type 1 diabetes, the current status of therapeutic interventions, and much more. Visit https://doi.org/10.1016/j.aace.2022.01.001 to read the full AACE Clinical Case Report.

In just two short years it is projected that 25 percent of all students in American schools will be English Language Learners (ELL). Are our schools prepared for that? Seasoned educator Andrea Bitner helps us understand the explosion in ELL students and how our school systems can best handle this change. Bitner, an educator for 23 years, fills us in on the unique challenges of teachers and schools as they prepare to cater to these students' distinctive needs, illuminating the paths to progress. Communication strategies with the parents of multilingual students are critical, along with a commitment to empathy in education. She shares her groundbreaking AACE system and some of the currently available assistive technologies that can help foster a conducive learning environment for ELL students.Bitner is also an author and speaker who travels the country providing resources to help educators better teach, connect and communicate with their ELL students and families. She is the author of "Take Me Home," in which she shares the true and inspiring stories of 11 of her former students through first-hand accounts of what it's really like to be bilingual in the American school system. (The book includes English and Spanish versions under the same cover.) Find out more about Andrea, her speaking services and other ELL resources at andreabitnerbooks.com or email her at 4andreabitner@gmail.com. "Outliers in Education" is a project of CEE, The Center for Educational Effectiveness. Find out more at effectiveness.org.Produced by Howell at the Moon Productions.

Justin talks with the Foundation's new Executive Director, Aleksandra, about her background and why she wanted to be a part of the mission. They discuss the Code Official Safety Specialist training, fallacies, professionalism, and a joint effort with ICC, AACE, NACA, and CEOSF. 

Today I am relasinng a podcast workshop I gave with the wonderful Janet McMordie of Second Act Actors Podcast live from the Association Of Actinf Educators and Coaches Conference.  If you have ever been curious about startgin your own podcast or wondered what goes on behind the scenes today's episode is sure to get your creative juices flowing. Enjoy!! Connect with Cue To Cue:  I: @thisischelseajohnson F: @thisischelseajohnson W https://thisischelseajohnson.com/

Join endocrine experts Karl Nadolsky, DO, DABOM, and Vin Tangpricha, MD, PhD, FACE, as they discuss the 2023 AACE Consensus Statement: Addressing Stigma and Bias in the Diagnosis and Management of Patients with Obesity/Adiposity-Based Chronic Disease and Assessing Bias and Stigmatization as Determinants of Disease Severity. Key topics include defining weight stigma, bias, and internalized weight bias (IWB), empowering patients and our global society to address obesity as a chronic disease, intervention recommendations using the 5A model, and much more. Visit https://www.endocrinepractice.org/article/S1530-891X(23)00335-X/fulltext to view the consensus statement in the June 2023 issue of Endocrine Practice.

In this What's Up Wednesday episode of the Gaining Health podcast, host Karli Burridge reviews some of the highlights of the American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update, which was released May 2023.Full the full Consensus Statement, click HERESupport the showThe Gaining Health Podcast will release a new episode monthly, every second Wednesday of the month. Episodes including interviews with obesity experts as well as scientific updates and new guidelines for the management of obesity.If you're a clinician or organization looking to start or optimize an obesity management program, and you want additional support and resources, check out the Gaining Health website! We offer monthly and annual Memberships, which include live group coaching, a community forum to ask questions and post resources, pre-recorded Master Classes, digital resources inlcuding patient education materials and office forms, and much more! We also sell our popular Gaining Health products, including a book on developing an obesity management program, editable forms and templates, and patient education materials in our Gaining Health Shop! If you are loving this podcast, please consider supporting us on Patreon

A wee bonus episode for you all! This is the live recording of my workshop at the AACE (Association of Acting Coaches & Educators) conference!Get ready to dive into the fascinating world of podcasting alongside Chelsea and I!In this lively session, we explore our captivating journey in the podcasting realm, uncovering secrets to becoming a stellar podcast guest or host. We'll also discuss the countless reasons why we adore this remarkable medium. Tune in now and bask in the joy of podcasting goodness! AACE websiteSecond Act ActorsCue To Cue Podcast Hosted on Acast. See acast.com/privacy for more information.

Are you an acting coach but can't find a community to guide you? Are you an acting educator who wants to update your teaching skills and knowledge?  In this week's episode, Actor/Painter/Teacher/Activist, Jennifer Wigmore would take us on a journey on how AACE was established to create a community amongst acting coaches and educators in Canada. AACE members share best practices and create standards for performers and workers in the entertainment industry. Together we can make acting training safer and  more empowering for everyone! In this episode: How an unfortunate casting experience evolved into Jennifer's green light to quit acting. How pursuing another artistic passion lead Jen to discover all creative endeavours are drawn from the same well. Just because you're a good actor doesn't mean you're a good teacher; sometimes your acting experience does not correlate into good teaching skills. The conversations about what we need to know as acting coaches and educators have changed so much that everyone needs to update their knowledge about how to create respect based classrooms and how not to hurt people. A little about Jennifer: Jennifer is a multidisciplinary artist in acting, writing, and visual art, and has worked for over twenty years as a professional artist. She has performed in theatre's across Canada including The Arts Club, Citadel Theatre, Tarragon Theatre, Theatre Center, Canadian Stage Company and the Stratford Festival. Jennifer has also appeared in numerous television series and films including; Dream Scenario, Christmas as the Drive In, The Winter Palace, Y: The Last Man, Malory Towers, Adult Adoption, Happy Place, Designated Survivor, Anne with an E, Impulse, Killjoys, Suits, Kart Racer, Little Men, and I Was a Sixth Grade Alien. She has just been cast as Chief April Anderson in the highly anticipated series Cross, based on James Pattersons novels, starring Aldis Hodge. She also narrated Todd Babiak's novel, The Spirits Up. She completed her BFA and MFA at OCAD University and continues to work as an acting coach and educator as well as a painting instructor. In addition to being a core member of the activist group Got Your Back, Jennifer is also a coordinator and steering committee member for AACE – The Association of Acting Coaches and Educators. Jennifer is also currently writing her first play called Measure Follow Jennifer! Online: jenniferwigmore.com,  aactingcoacheseducators.com Instagram: @jenniferwigmore @jenniferwigmoreart @aactingcoacheseducators Facebook: Jennifer Wigmore Jennifer Wigmore Art AACE – Association of Acting Coaches and Educators  

Join endocrine experts Irl Hirsch, MD, Susan L. Samson, M.D., Ph.D., FRCPC, FACE, and Vin Tangpricha, MD, PhD, FACE, as they discuss the latest updates to AACE's 2023 diabetes algorithm, which provides concise guidance to assist health care professionals in clinical decision-making for the management of Type 2 diabetes (T2D). Learn how to leverage the algorithm to improve patient care, how someone's risk for hypoglycemia impacts their individual target, when to use a complications-centric and glucose-centric approach to choosing first-line therapy for glycemic control, and much more. Visit https://doi.org/10.1016/j.eprac.2023.02.001 to view the full algorithm in the May 2023 issue of Endocrine Practice.

Nonalcoholic fatty liver disease (NAFLD) is a major health problem that is closely linked to the epidemics of obesity and type 2 diabetes mellitus. Join endocrine experts Betul Hatipoglu MD, Professor of Medicine at CWRU School of Medicine, and Medical Director for Diabetes & Obesity Center at University Hospital Cleveland Medical Center, and Sangeeta Kashyap MD, Assistant Chief of Clinical Affairs at New York-Presbyterian/Weill Cornell Medical Center, to learn how to diagnose and manage NAFLD and NASH in primary care and endocrinology clinical settings. Key topics include screening for NAFLD/NASH, and the latest management recommendations including supplements, medications, bariatric surgery, and more.

In this podcast endocrine expert David C. Lieb, MD, FACP, FACE, interviews our AACE 2023 award-winning plenary speakers, Elizabeth N. Pearce, MD, MSc, FACE, Irl Hirsch, MD, and Richard J. Auchus, MD, PhD, FACE, about the latest advancements in thyroid disease, diabetes, and adrenal disease. Key topics include iodine deficiency, adjusting thyroid medication doses, the future of insulin therapy, GMI compared to A1C levels, screening for primary aldosteronism, Cushing's syndrome, adrenal steroid profiling, and more. 

There is varying knowledge among members of the endocrine care team about the vaccines AACE recommends for persons with diabetes that are included in the updated 2022 AACE Diabetes Guideline. In this podcast endocrine expert Vin Tangpricha, MD, PhD, interviews internationally known clinician, epidemiologist, and Interim Dean of Emory University School of Medicine, Carlos del Rio, MD, about the importance of vaccines, how vaccines are made, developed, and approved, and how to use this information to address patients' questions or hesitancy towards vaccines.

This week, SurfingNASH is offering conversation segments to showcase our new series, The NASH Tsunami in Diabetes: Getting Ahead of the Rising Tide. Rising Tide, as we call it, is a subscription-only series targeted at the primary care physicians, endocrinologists and allied health professionals who provide front-line treatments for patients living with Type 2 Diabetes and/or obesity.This sample session comes from the debut episode which focuses on research that has led AACE to issue guidelines, AGA to propose clinical care pathways and AHA to produce a white paper on the links between Fatty Liver Disease and CVD Risk. Endocrinology researcher and key opinion leader Ken Cusi discusses his work looking at NAFLD and NASH in diabetic patient populations. He covers studies confirming that patients with diabetes are at least twice as likely to have NAFLD or NASH as non-diabetics. He notes that this effect is confirmed in overweight as well as obese patients and is proven independent of obesity (an important note: the two together are worse than either alone). In practical terms, he asserts that primary care and endocrinology clinics are the places we can identify NAFLD and early NASH before these become later-stage fibrosis or cirrhosis requiring attention from hepatologists. In that context, he notes that twice as many patients in an endocrinology clinic will test positive for NAFLD or NASH compared to a primary care clinic, thus making endocrinologists a vital target group for earlier identification and treatment of Fatty Liver Disease. In his practice, Ken advocates for every patient to receive a FIB-4 test, which can be found in most EMR systems and is an inexpensive, reasonably reliable negative predictor for F3 or F4 status.Next, hepatology researcher and key opinion leader Kathleen Corey discusses some of her research on the link between CVD and NAFLD. Two key conclusions: over a relatively short period after initial induction into the study (median of 25.5 months), the presence of NAFLD causes a 70% increase in relative risk (4.1% vs. 2.6%) of a Major Adverse Cardiovascular Event (MACE). She agrees with Ken's suggestion about FIB-4. She also notes the trend of primary care physicians to discontinue statins if the patient's ALT level starts to rise and cautions that this step is likely to increase patient risk.Finally, Kay Pepin, Director of Research Translation for Resoundant Inc. under joint appointment with the Mayo Clinic, discusses research demonstrating that a relatively simple MRE session can provide the information necessary to determine the likelihood that fibrosis will advance to cirrhosis or compensated cirrhosis will advance to decompensated states. She also notes that with insurance coverage, this is not an expensive test for many people. By adding a simple MRI module to the MRE session, physicians can derive a significant amount of additional information.If you enjoy this preview, please visit our website and sign up to listen to the full episode and more exclusive content. We also kindly ask that you submit reviews wherever you download our discussions or, alternatively, write to us directly at questions@SurfingNASH.com.The Rising Tide podcast series and all the episodes are produced under a non-restricted grant from Novo Nordisk. Novo Nordisk has neither influenced nor reviewed the contents of this podcast in any way. This content represents the views of the speakers and does not necessarily represent the views of Novo Nordisk. The content herein is for educational purposes only and should not be taken as medical advice.

This week, SurfingNASH is offering conversation segments to showcase our new series, The NASH Tsunami in Diabetes: Getting Ahead of the Rising Tide. Rising Tide, as we call it, is a subscription-only series targeted at the primary care physicians, endocrinologists and allied health professionals who provide front-line treatments for patients living with Type 2 Diabetes and/or obesity. This preview comes from our second episode which focused on the new AACE Fatty Liver Guidelines.The panelists include four authors of the guidelines: first author Dr. Ken Cusi from the University of Florida, third author Dr. Diana Barb, also from the University of Florida, and the two leading AASLD representatives in this project, Dr. Zobair Younossi of INOVA Health Systems and Dr. Maru Rinella of the University of Chicago. Dr. Younossi focuses his discussion on the epidemiology of the disease and what it suggests in terms of treatment goals and priorities. Dr. Cusi identifies the two main messages of the guidelines: the importance of FIB-4 as a screening tool and the fact that even today, with no recently approved NASH drugs on the market, there are therapeutic choices providers can make that will benefit NASH patients. Dr. Barb discusses in detail prescribing decisions that can benefit diabetes patients at risk of progressing to significant NASH fibrosis and beyond. Dr. Rinella lends comments throughout from her own perspective and that of AASLD. This fast-paced episode provides a tremendous amount of information while remaining accessible and easy to follow.If you enjoy the preview, please visit our website and sign up or sign in to listen to the full episode and more exclusive content. We also kindly ask that you submit reviews wherever you download our discussions or, alternatively, write to us directly at questions@SurfingNASH.com.The Rising Tide podcast series and all the episodes are produced under a non-restricted grant from Novo Nordisk. Novo Nordisk has neither influenced nor reviewed the contents of this podcast in any way. This content represents the views of the speakers and does not necessarily represent the views of Novo Nordisk. The content herein is for educational purposes only and should not be taken as medical advice.

This week, SurfingNASH is offering conversation segments to showcase our new series, The NASH Tsunami in Diabetes: Getting Ahead of the Rising Tide. Rising Tide, as we call it, is a subscription-only series targeted at the primary care physicians, endocrinologists and allied health professionals who provide front-line treatments for patients living with Type 2 Diabetes and/or obesity. This preview looks at drug choices prescribers can make today for patients with Type 2 Diabetes Mellitus and obesity that have positive impact on Fatty Liver disease. In addition to co-hosts Dr. Ken Cusi and Roger Green, panelists for this discussion include endocrinologist Dr. Scott Isaacs, second author of the recent AACE guidelines, and hepatology researcher Dr. Naim Alkhouri.Ken notes that we are living in a period where the paradigm around treating chronic metabolic conditions is shifting. In a world where one in five patients with T2DM lives with clinically significant fibrosis, Ken states providers can no longer ignore the liver when making treatment decisions about diabetes. He also suggests that hepatologists need to become more comfortable using medications that were previously reserved for diabetes.At this point, Naim and Scott join the conversation. Naim begins by discussing EDICT, a trial that compared the standard T2DM regimen of the day (metformin, followed by the sulfonylurea glipizide and then insulin) to a first-line combination therapy of metformin, the GLP-1 agonist exenatide and the PPAR pioglitazone. At the end of this six-year period, the researchers found meaningful, statistically significant differences in three key Fatty Liver parameters: prevalence of NAFLD (69% vs. 31%); clinically significant fibrosis (26% vs. 7%); and percentage fat in the liver (12.5% vs. 8.5%). It also found that patients achieved a lower HbA1c level (6.0% with the combination, vs. 6.8% in the standard treatment group).In response to a question from Roger, Ken identifies three majors lessons of the last 10 years:7 of 10 Americans with T2D have a fatty liver; those with NAFLD but not T2D see their chances of becoming diabetic and , separately, developing cardiovascular disease double.15-20% of Americans with T2D also exhibit moderate-to-advanced cirrhosis.GLP-1s, as a class, address multiple factors of chronic metabolic disease. They reduced HbA1c, promote and maintain significant weight loss, and slow progression of fibrosis.Naim expresses a concern that many doctors treating patients with T2D do not consider NASH. A Cleveland Clinic assessment of ICD-10 codes demonstrated that only 5% of T2D patients were coded for NAFLD. This means the 2/3 of the T2D patients in that system have fatty livers and were never evaluated! Similarly, ~2/3 of the patients who present with cirrhosis in his clinic were never told that they had NAFLD. In Naim's view, NAFLD should be a disease for primary care and endocrinology to treat, while it should be hepatologists that treat NASH.If you enjoy this preview, please visit our website and sign up to listen to the full episode and more exclusive content. We also kindly ask that you submit reviews wherever you download our discussions or write to us directly at questions@SurfingNASH.com.The Rising Tide podcast series and all the episodes are produced under a non-restricted grant from Novo Nordisk. Novo Nordisk has neither influenced nor reviewed the contents of this podcast in any way. This content represents the views of the speakers and does not necessarily represent the views of Novo Nordisk. The content herein is for educational purposes only and should not be taken as medical advice.

Join endocrine experts S. Sethu K. Reddy, MD, MBA, FRCPC, FACP, MACE, Susan L. Samson, MD, PhD, FRCPC, FACE, and Vin Tangpricha, MD, FACE, as they discuss the 2022 AACE diabetes clinical practice guideline featuring 170 updated and new evidence-based recommendations for the care and management of people with or at risk for diabetes mellitus. Key topics include how to use the guideline in your practice, new content developed on hypoglycemia, secondary diabetes approaches, supplements, social determinants of health, and more. Plus, get an inside sneak peek into the development of a diabetes care algorithm coming soon. Visit https://www.endocrinepractice.org/article/S1530-891X(22)00576-6/fulltext to view the full guideline published in the October 2022 issue of Endocrine Practice.

Credits: 0.25 AMA PRA Category 1 Credit™     CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-302   Overview: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the United States, with a prevalence rate of more than 30% of US adults. Most have not been diagnosed or treated. Join us to discuss the new AACE guidance on the diagnosis and treatment of NAFLD to reduce the burden of this common disease.   Episode resource links: AACE Guideline:  Endocrine Pract: May 2022, 28(5): 528-562 Coffee: Front Pharmacol. 2021 Dec 13;12:786596. doi: 10.3389/fphar.2021.786596   Guest: Robert A. Baldor, MD   Music Credit: Richard Onorato  

Credits: 0.25 AMA PRA Category 1 Credit™     CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-302   Overview: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the United States, with a prevalence rate of more than 30% of US adults. Most have not been diagnosed or treated. Join us to discuss the new AACE guidance on the diagnosis and treatment of NAFLD to reduce the burden of this common disease.   Episode resource links: AACE Guideline:  Endocrine Pract: May 2022, 28(5): 528-562 Coffee: Front Pharmacol. 2021 Dec 13;12:786596. doi: 10.3389/fphar.2021.786596   Guest: Robert A. Baldor, MD   Music Credit: Richard Onorato  

For persons with diabetes, vaccinations have been shown to help them from contracting and experiencing more severe outcomes from preventable illnesses, such as influenza and Covid-19.It is important for the endocrine care team to learn practical strategies for increasing vaccination rates for their patients with diabetes. Join endocrine experts Geetha Gopalakrishnan, MD, FACE and David C. Lieb, MD, FACE as they share their perspectives and experiences on advancing immunizations by using the CDC's Standards for Adult Immunization Practice and working to build a practice culture of vaccine confidence. Visit www.AACE.com/immunization for additional education and resources.